Guhan Pharmaceutical Group Co., Ltd. (SHE:000590)
China · Delayed Price · Currency is CNY 9.27
-0.19 (-2.01%)
Sep 10, 2026, 3:04 PM CST
SHE:000590 Revenue
Guhan Pharmaceutical Group had revenue of 62.51M CNY in the quarter ending June 30, 2026, a decrease of -19.05%. This brings the company's revenue in the last twelve months to 329.41M, down -2.83% year-over-year. In the year 2025, Guhan Pharmaceutical Group had annual revenue of 337.67M, down -1.61%.
Revenue (ttm)
329.41M
Revenue Growth
-2.83%
P/S Ratio
6.88
Revenue / Employee
309.60K
Employees
1,064
Market Cap
2.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 337.67M | -5.53M | -1.61% |
| Dec 31, 2024 | 343.21M | -61.44M | -15.18% |
| Dec 31, 2023 | 404.65M | 54.12M | 15.44% |
| Jan 1, 2023 | 350.53M | 49.75M | 16.54% |
| Jan 1, 2022 | 300.77M | 25.68M | 9.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Enwei Pharmaceutical | 826.13M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Anhui Huangshan Capsule | 407.10M |
| Qinghai Spring Medicinal Resources Technology | 303.67M |